A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|67|12|3104-3112

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.12, 2015-12, pp. : 3104-3112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Certolizumab pegol for the treatment of rheumatoid arthritis

By Modesto I   Spinello M   Nicchi F   Cottone M  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 391-402

Future Medicine

Access to resources Recommend Favorite

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 2, 2015-02 ,pp. : 151-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 668-677

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 8, 2015-08 ,pp. : 866-874

John Wiley & Sons Inc

Access to resources Recommend Favorite

What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1202-1209

John Wiley & Sons Inc

Access to resources Recommend Favorite